This Article Full Text Full Text (PDF) An erratum has been published eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Related articles in The Oncologist Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Biganzoli, L. Articles by Twelves, C. Search for Related Content PubMed PubMed Citation Articles by Biganzoli, L. Articles by Twelves, C.

Moving Forward with Capecitabine: a Glimpse of the Future

^a EORTC Investigational Drug Branch for Breast Cancer, Chemotherapy Unit, Institut Jules Bordet, Brussels, Belgium; ^b Hospital Universitario San Carlos, Servicio de Oncologia Médica, Madrid, Spain; ^c Cancer Research UK, Department of Medical Oncology, University of Glasgow and Beatson Oncology Centre, Glasgow, United Kingdom

Correspondence: Laura Biganzoli, M.D., EORTC Investigational Drug Branch for Breast Cancer, Chemotherapy Unit, Institut Jules Bordet, Boulevard de Waterloo 125, 1000 Brussels, Belgium. Telephone: 32-2-541-3188; Fax: 32-2-541-3199; e-mail: laura.biganzoli{at}bordet.be

Oral capecitabine is a useful chemotherapy for metastatic breast cancer, both as monotherapy and in combination with other cytotoxic drugs. The proven activity of capecitabine has provided the rationale to explore its use earlier in the course of the disease and in combination with other agents, particularly those known to further upregulate thymidine phosphorylase (TP) concentrations in tumor tissue.

The efficacy and safety of capecitabine monotherapy compares favorably with cyclophosphamide/methotrexate/5-fluorouracil in chemotherapy-naïve patients and with paclitaxel in anthracycline-pretreated patients. Therefore, for patients whose disease has progressed during or following anthracycline treatment, but for whom capecitabine/docetaxel combination therapy or taxane monotherapy is not appropriate, capecitabine monotherapy is an attractive alternative to established i.v. treatments.

In combination, capecitabine plus paclitaxel, which further upregulates TP in tumor tissue, has demonstrated high activity in two phase II studies in advanced/metastatic breast cancer. Similarly, combination with vinorelbine showed promising activity in pretreated metastatic breast cancer patients, and triple combinations with an anthracycline and a taxane or cyclophosphamide have proven to be highly active. In the future, capecitabine may be combined with novel biologic agents, such as trastuzumab and bevacizumab; the former combination has already shown encouraging results in a pilot trial. Confirmatory studies for many of these combinations and phase III trials versus standard therapy are now warranted.

Key Words. Capecitabine • Taxanes • Breast cancer • Trastuzumab • Vinorelbine • Anthracyclines

Related articles in The Oncologist:

Moving Forward with Capecitabine: A Glimpse of the Future

Laura Biganzoli, Miguel Martin, and Chris Twelves
The Oncologist 2003 8: 124. [Full Text]  

This article has been cited by other articles:

				D. K. Armstrong Topotecan Dosing Guidelines in Ovarian Cancer: Reduction and Management of Hematologic Toxicity Oncologist, February 1, 2004; 9(1): 33 - 42. [Abstract] [Full Text] [PDF]